Dr. Papadimitrakopoulou on Treatment Options for EGFR-Mutant NSCLC

Vassiliki A. Papadimitrakopoulou, MD
Published: Friday, Jun 02, 2017



Vassiliki A. Papadimitrakopoulou, MD, professor, Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses treatment options for patients with EGFR-mutant non-small cell lung cancer (NSCLC).

There are multiple options for first-line therapy for patients with EGFR-mutant NSCLC, explains Papadimitrakopoulou. The first-generation EGFR tyrosine kinase inhibitors (TKI’s) are actively being used in the community and academic setting.

Second-line therapy for patients who have developed a resistance to first-generation EGFR TKI’s has been dominated by the FDA approval of osimertinib (Tagrisso), states Papadimitrakopoulou. Osimertinib has become the standard of care for patients whose tumors have developed a T790M mutation.



Vassiliki A. Papadimitrakopoulou, MD, professor, Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses treatment options for patients with EGFR-mutant non-small cell lung cancer (NSCLC).

There are multiple options for first-line therapy for patients with EGFR-mutant NSCLC, explains Papadimitrakopoulou. The first-generation EGFR tyrosine kinase inhibitors (TKI’s) are actively being used in the community and academic setting.

Second-line therapy for patients who have developed a resistance to first-generation EGFR TKI’s has been dominated by the FDA approval of osimertinib (Tagrisso), states Papadimitrakopoulou. Osimertinib has become the standard of care for patients whose tumors have developed a T790M mutation.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: ALK-Positive NSCLC: Emerging Strategies to Inform Sequencing, Optimize Outcomes, and Address Unmet Clinical Needs Along the Disease ContinuumAug 29, 20181.5
Community Practice Connections™: Oncogenic Tumor Board in Advanced NSCLC: Leveraging Actionable Mutations Along the Disease Continuum to Optimize Patient OutcomesAug 30, 20182.0
Publication Bottom Border
Border Publication
x